PMID- 16178970
OWN - NLM
STAT- MEDLINE
DCOM- 20051108
LR  - 20220311
IS  - 1083-4389 (Print)
IS  - 1083-4389 (Linking)
VI  - 10 Suppl 1
DP  - 2005
TI  - Treatment of Helicobacter pylori.
PG  - 40-6
AB  - The efficacy of established Helicobacter pylori regimes needs to be reviewed. In 
      view of drug resistance, side effects, and compliance and expense of therapy, 
      treatment failure is increasing and second-line treatment strategies need to be 
      developed. A simulation model suggested by the Cochrane review group showed that 
      H. pylori eradication is cost-effective for duodenal and gastric ulcer long-term. 
      The duration of eradication therapy continues to be controversial. In Europe and 
      other parts of the world, 7-day triple regimes are used, whereas guidelines from 
      the United States recommend 10-14 days of therapy. Antibiotic resistance is a 
      major factor affecting the outcome of eradication therapy. New modified 
      eradication regimes involve substitution of antibiotics used in conjunction with 
      other drugs. The newer generation fluoroquinolones have shown some promise as 
      part of an eradication regimen. Quadruple therapy (bismuth, proton pump inhibitor 
      [PPI] and two antibiotics and sequential treatment [PPI with three antibiotics]) 
      are promising first-line treatments. Novel agents have been tried, but with 
      disappointing results. New drugs and administration forms have been reported but 
      their efficacy needs confirmation.
FAU - Bytzer, Peter
AU  - Bytzer P
AD  - Department of Medical Gastroenterology, Glostrup University Hospital, DK-2600 
      Glostrup, Denmark. peter.bytzer@dadlnet.dk
FAU - O'Morain, Colm
AU  - O'Morain C
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Ulcer Agents)
SB  - IM
MH  - Anti-Bacterial Agents/administration & dosage/*pharmacology/*therapeutic use
MH  - Anti-Ulcer Agents/administration & dosage/pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Resistance, Bacterial
MH  - Drug Therapy, Combination
MH  - Helicobacter Infections/*drug therapy
MH  - Helicobacter pylori/*drug effects
MH  - Humans
MH  - Peptic Ulcer/*drug therapy/microbiology
MH  - Treatment Failure
MH  - Treatment Outcome
RF  - 52
EDAT- 2005/09/24 09:00
MHDA- 2005/11/09 09:00
CRDT- 2005/09/24 09:00
PHST- 2005/09/24 09:00 [pubmed]
PHST- 2005/11/09 09:00 [medline]
PHST- 2005/09/24 09:00 [entrez]
AID - HEL333 [pii]
AID - 10.1111/j.1523-5378.2005.00333.x [doi]
PST - ppublish
SO  - Helicobacter. 2005;10 Suppl 1:40-6. doi: 10.1111/j.1523-5378.2005.00333.x.